Plastic and reconstructive surgery · 2024
Long-Term Surgical Outcomes of Intermediate Cleft Rhinoplasty.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ng Jinggang J, Cheung Liana, Massenburg Benjamin B, Cho Daniel Y, Wu Meagan, Romeo Dominic J, Swanson Jordan W, Jackson Oksana A, Low David W, Taylor Jesse A
Аннотация
BACKGROUND: The risk-to-benefit ratio of operating on the cleft nasal deformity in the period of mixed dentition remains debated. This study characterizes the authors' 18-year experience with intermediate cleft rhinoplasties to add data and nuance to the discussion.
METHODS: The authors performed a retrospective cohort study of patients who underwent intermediate cleft rhinoplasty from 2006 to 2023. Demographic information and operative details were collected. Primary outcomes were operative complications and need for subsequent rhinoplasty.
RESULTS: A total of 342 patients undergoing 372 intermediate rhinoplasties were included: 150 (40.3%) with no graft/implant, 165 (44.4%) with iliac crest cartilage graft, 36 (9.7%) with ear cartilage, 19 (5.1%) with a resorbable plate, and 3 (0.8%) with nasal cartilage. Use of iliac crest graft predicted fewer subsequent rhinoplasties independent of age at surgery, age at most recent follow-up, sex, race, syndromic status, cleft severity, intranasal stenting duration, and surgeon (β = -0.234; P = 0.012). Use of a V-Y chondromucosal flap in the unilateral cleft lip group (β = -0.401; P = 0.002) and placement of a columellar strut graft in the bilateral cleft lip group (β = -0.450; P = 0.028) predicted fewer subsequent rhinoplasties. The proportion of rhinoplasties using iliac crest grafts increased over time ( r [372] = 0.806; P < 0.001). Most patients (55.0%) with follow-up beyond age 18 years ( n = 60) did not require subsequent rhinoplasty.
CONCLUSIONS: Iliac crest cartilage grafting as a columellar strut in bilateral clefts and a chondromucosal V-Y advancement in unilateral clefts were associated with a decreased need for future rhinoplasty. Further work is needed to understand the risk-to-benefit ratio, surgical burden, and patient-reported outcomes of intermediate rhinoplasty.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
METHODS: The authors performed a retrospective cohort study of patients who underwent intermediate cleft rhinoplasty from 2006 to 2023. Demographic information and operative details were collected. Primary outcomes were operative complications and need for subsequent rhinoplasty.
RESULTS: A total of 342 patients undergoing 372 intermediate rhinoplasties were included: 150 (40.3%) with no graft/implant, 165 (44.4%) with iliac crest cartilage graft, 36 (9.7%) with ear cartilage, 19 (5.1%) with a resorbable plate, and 3 (0.8%) with nasal cartilage. Use of iliac crest graft predicted fewer subsequent rhinoplasties independent of age at surgery, age at most recent follow-up, sex, race, syndromic status, cleft severity, intranasal stenting duration, and surgeon (β = -0.234; P = 0.012). Use of a V-Y chondromucosal flap in the unilateral cleft lip group (β = -0.401; P = 0.002) and placement of a columellar strut graft in the bilateral cleft lip group (β = -0.450; P = 0.028) predicted fewer subsequent rhinoplasties. The proportion of rhinoplasties using iliac crest grafts increased over time ( r [372] = 0.806; P < 0.001). Most patients (55.0%) with follow-up beyond age 18 years ( n = 60) did not require subsequent rhinoplasty.
CONCLUSIONS: Iliac crest cartilage grafting as a columellar strut in bilateral clefts and a chondromucosal V-Y advancement in unilateral clefts were associated with a decreased need for future rhinoplasty. Further work is needed to understand the risk-to-benefit ratio, surgical burden, and patient-reported outcomes of intermediate rhinoplasty.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.